Adiso Therapeutics Announces Positive Topline Data from Phase 1b Study of ADS051 for the Treatment of Moderate-to-Severe Ulcerative Colitis
Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of...